Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors

References

• Carroll MW Moss B. Poxviruses as expressions vectors. CUI7: Opin. Biotechnol (8), 573–577 (1997).
   Google Scholar
• Moss B. Poxviridae: the Viruses and their Replication. In: Fields Virology. Lippincott Williams & Wilkins, NY, USA, 2 (83), 2637–2671 (1996).
   Google Scholar
• ••Good overview of the biological relevance of poxviruses.
   Google Scholar
• Singh DS, Tartaglia J. Poxviruses as Immunization Vehicles. In: Vaccines. Plotkin SA, Orenstein WA (Eds), Saunders, PA, USA, 1297–1316 (2004).
   Google Scholar
• •Overview of preclinical and clinical data from poxviruses.
   Google Scholar
• Henderson DA, Borio LL, Lane JM. Smallpox and Vaccinia. In: Vaccines. Plotkin SA, Orenstein WA (Eds), Saunders, PA, USA, 123–153 (2004).
   Google Scholar
• Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a non-human mammalian cell line. Virology (238), 198–211 (1997).
   PubMed Web of Science ®Google Scholar
• Mayr A, Hochstein-Mintzel V, Stick]. H. Abstammung, Eigenschaften und Verwendung des attenuieten Vaccinia-Stammes MVA. Infection 3, 6–14 (1975).
   Google Scholar
• Tartaglia J, Perkus ME, Taylor J et al NYVAC: A highly attenuated strain of vaccinia virus. Virology188 (1), 217–232 (1992).
   PubMed Web of Science ®Google Scholar
• Perkus ME, Tartaglia J, Paoletti E. Poxvirus-based vaccine candidates for cancer, AIDS and infectious diseases. Leukocyte Biology58, 1–13 (1995).
   Google Scholar
• Paoletti E. Applications of poxvirus vectors to vaccination: An update. Proc. Natl Acad. Sci. 93,11349–11353 (1996).
   PubMed Web of Science ®Google Scholar
• Esposito JJ. Poxviridae. In: Classification and Nomenclature of Viruses. Francki RIB, Fauquet CM, Knudson DL, Brown F (Eds), Springer-Verlag, NY, USA, 91–102 (1991).
   Google Scholar
• Taylor J, Meignier B, Tartaglia J et al. Biological and immunogenic properties of canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 14, 428–434 (1996).
   Google Scholar
• Somogyi P, Frazier J, Skinner MA. Fowlpox virus host-range restriction: gene expression, DNA replication and morphogenesis in non-permissive mammalian cells. Virology197,439–444 (1993).
   PubMed Web of Science ®Google Scholar
• Poulet H, Brunet S, Boularand C et al Efficacy of a canarypoxvirus-vectored vaccine against feline leukemia. The Veterinary Recorr1153, 141–145 (2003).
   Google Scholar
• Tartaglia J, Benson J, Cornet B et al. Potential improvements for poxvirus-based immunization vehicles. In: Onzieme Colloque des Cent Carries. Girard M, Dodet B (Eds), Pasteur Merieux, Marnes-La Coquette, Paris, France, 187–197 (1997).
   Google Scholar
• Novembre FJ, Saucier M, Anderson DC et al Development of AIDS in a chimpanzee infected with human immunodeficiency virus type 1*.1. Viral 71(5), 4086–4091 (1997).
   Google Scholar
• Warren J. Preclinical AIDS vaccine research: survey of SW, SHIV and HIV challenge studies in vaccinated nonhuman primates. .1. Med. Primatol 31 (4–5), 237–256 (2002).
   Google Scholar
• •Clearly reviews the primate HIV vaccine literature.
   Google Scholar
• Bogers WM, Cheng-Meyer C, Montelaro RC. Developments in preclinical AIDS vaccine efficacy models. AIDS14\(Suppl. 3), S141—S151 (2000).
   Google Scholar
• Girard M, van der RE, Barre-Sinoussi F et al Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus. Virology232(1), 98–104 (1997).
   Google Scholar
• Patterson LJ, Peng B, Abimiku AG et al. Cross-protection in NYVAC—HIV-1-immunized/HIV-2-challenged but not in NYVAC—HIV-2-immunized/SHIV-challenged rhesus macaques. AIDS14(16), 2445–55 (2000).
   Google Scholar
• Franchini G, Robert-Guroff M, Tartaglia J et al Highly attenuated HIV type 2* recombinant poxviruses but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques. AIDS Res. Hum. Retrovir. 11(8), 909–920 (1995).
   Google Scholar
• Abimiku AG, Franchini G, Tartaglia J et al HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nature Med. 1(4), 321–329 (1995).
   Google Scholar
• Myagkikh M, Alipanah S, Markham PD et al Multiple immunizations with attenuated poxvirus HIV type 2* recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res. Hum. Retrovir. 12(11), 985–992 (1996).
   Google Scholar
• Walther-Jallow L, Nilsson C, Soderlund J et al Cross-protection against mucosal simian immunodeficiency virus (SIVsm) challenge in human immunodeficiency virus type 2*-vaccinated cynomolgus monkeys. j Gen. Viral 82 (Pt 7), 1601–1612 (2001).
   Google Scholar
• Andersson S, Makitalo B, Thorstensson R et al Immunogenicity and protective efficacy of a human immunodeficiency virus type 2* recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. j Infect. Drs. 174(5), 977–985 (1996).
   Google Scholar
• Leno M, Carter L, Venzon DJ et al Induction of CD8+ lymphocyte antiviral activity in monkeys immunized with SW recombinant poxvirus vaccines: potential role in vaccine efficacy. AIDS Res. Hum. Retrovir (15), 461–470 (1999).
   Google Scholar
• Vogt G, Le Grand R, Vaslin B et al Heterologous HIV-2 challenge of rhesus monkeys immunized with recombinant vaccinia viruses and purified recombinant HIV-2 proteins. Vaccine 13(2), 202–208 (1995).
   Google Scholar
• Shafferman A, Jahrling PB, Benveniste RE et al Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1* sequences. Proc. Natl Acad. Sci. USA 88(16), 7126–7130 (1991).
   Google Scholar
• Hu SL, Abrams K, Barber GN et al Protection of macaques against SW infection by subunit vaccines of SW envelope glycoprotein gp160. Science 255(5043), 456–459 (1992).
   Google Scholar
• Haigwood NL, Pierce CC, Robertson MN et al Protection from pathogenic SW challenge using multigenic DNA vaccines. Immunol Lett. 66(1-3), 183–188 (1999).
   Google Scholar
• Cole KS, Rowles JL, Jagerski BA et al Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. Viral 71(7), 5069–5079 (1997).
   Google Scholar
• Hulskotte EG, Geretti AM, Osterhaus AD. Towards an HIV-1 vaccine: lessons from studies in macaque models. Vaccine 16(9–10), 904–915 (1998).
   Google Scholar
• Lu S, Arthos J, Montefiori DC et al. Simian immunodeficiency virus DNA vaccine trial in macaques. j Vim'. 70(6), 3978–3991 (1996).
   Google Scholar
• Lu X, Kiyono H, Lu D et al Targeted lymph-node immunization with whole inactivated simian immunodeficiency virus (SIV) or envelope and core subunit antigen vaccines does not reliably protect rhesus macaques from vaginal challenge with SIVmac251. A/DS12(1), 1–10 (1998).
   Google Scholar
• Mortara L, Letourneur F, Gras-Masse H et al Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine. Viral 72(2), 1403–1410 (1998).
   PubMed Web of Science ®Google Scholar
• Pal R, Venzon D, Letvin NL et al ALVAC- SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIV(mac)-induced immunodeficiency. j Viral 76 (1), 292–302 (2001).
   Google Scholar
• Hu SL, Stallard V, Abrams K et al Protection of vaccinia-primed macaques against SIVmne infection by combination immunization with recombinant vaccinia virus and SIVmne gp160../. Med. Primatol 22(2–3), 92–99 (1993).
   Google Scholar
• Polacino P, Stallard V, KLaniecki JE et al Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen. I Viral 73 (1), 618–630 (1999).
   Google Scholar
• Daniel MD, Mazzara GP, Simon MA et al High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SW infection. AIDS Res. Hum. Retrovir10(7), 839–851 (1994).
   Google Scholar
• Hirsch VM, Fuerst TR, Sutter G et al Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SW) -infected macaques: effect of prior immunization with a trivalent SW vaccine in modified vaccinia virus Ankara. I Viral 70(6), 3741–3752 (1996).
   Google Scholar
• Ourmanov I, Brown CR, Moss B et al Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SW) Gag-P01 and/or Env in macaques challenged with pathogenic SIV. I Viral 74 (6), 2740–2751 (2000).
   Google Scholar
• Seth A, Ourmanov I, Schmitz JE et al Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SW) Gag—Poi primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SW challenge. J. Viral. 74(6), 2502–2509 (2000).
   PubMed Web of Science ®Google Scholar
• Nilsson C, Sutter G, Walther-Jallow L et al Immunization with recombinant modified vaccinia virus Ankara can modify mucosal simian immunodeficiency virus infection and delay disease progression in macaques. J Gen. Viral. 83(Pt 4), 807–818 (2002).
   Google Scholar
• Negri DR, Baroncelli S, Michelini Z et al Effect of vaccination with recombinant modified vaccinia virus Ankara expressing structural and regulatory genes of SIV(macJ5) on the kinetics of SW replication in cynomolgus monkeys. J. Med. Primatol 30(4), 197–206 (2001).
   Google Scholar
• Abimiku AG, Franchini G, Aldrich K et al. Humoral and cellular immune responses in rhesus macaques infected with human immunodeficiency virus type 2*. AIDS Res. Hum. Retrovir 11(3), 383–393 (1995).
   Google Scholar
• Benson J, Chougnet C, Robert-Guroff M et al Recombinant vaccine-induced protection against the highly pathogenic SIVmac251: dependence on route of challenge exposure. J Vim!. (72), 4170–4182 (1998).
   Google Scholar
• Hel Z, Nacsa J, Tryniszewska E et al Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4(+) and CD8(+) T-cell responses. J Immunol 169(9), 4778–4787 (2002).
   Google Scholar
• Van Rompay KK, Greenier JL, Cole KS et al Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. I Viral. 77(1), 179–190 (2003).
   Google Scholar
• Safrit JT, Ruprecht R, Ferrantelli F et al. Immunoprophylaxis to prevent mother-to-child transmission of HIV-1. I Acquir Immune De& Synth: (35), 169–177 (2004).
   PubMed Web of Science ®Google Scholar
• Casimiro DR, Bett AJ, Fu TM etal. Heterologous prime-boost HIV-1 immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors.' Vim!. (In Press) (2004).
   Google Scholar
• Stevceva L, Alvarez X, Lackner AA et al Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SW (gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques. J. Viral. 76 (22), 11659–71166 (2002).
   Google Scholar
• Schneider J, Gilbert SC, Blanchard TJ etal. Enhanced immunogenicity for CD8+ T-cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Med. 4(4), 397–402 (1998).
   Google Scholar
• Sedegah M, Jones TR, Kaur M et al Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Nat! Acad. Li. USA 95(13), 7648–7653 (1998).
   Google Scholar
• Hel Z, Tsai WP, Thornton A et al Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T-cell responses by a DNA-SW and NYVAC-SIV prime/boost regimen. Immunol 167(12), 7180–7191 (2001).
   Google Scholar
• Hanke T, McMichael A. Preclinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunol Lett. 66(1-3), 177–181 (1999).
   Google Scholar
• Buge SL, Ma HL, Amara RR et al Gp120- alum boosting of a Gag—Pol—Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge. AIDS Res. Hum. Retrovir. 19(10), 891–900 (2003).
   Google Scholar
• Hanke T, Samuel RV, Blanchard TJ et al Effective induction of simian immunodeficiency virus-specific cytotoxic T-lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus ankara boost vaccination regimen. I Vim!. 73(9), 7524–7532 (1999).
   Google Scholar
• Sharpe S, Hanke T, Tinsley-Bown A et al Mucosal immunization with PLGA-microencapsulated DNA primes a SW-specific CTL response revealed by boosting with cognate recombinant modified vaccinia virus Ankara. Virology313(1), 13–21 (2003).
   Google Scholar
• Allen TM, Vogel TU, Fuller DH et al Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J. Immunol 164(9), 4968–4978 (2000).
   PubMed Web of Science ®Google Scholar
• Doria-Rose NA, Ohlen C, Polacino P et al Multigene DNA priming-boosting vaccines protect macaques from acute CD4* T-Cell depletion after simian-human immunodeficiency virus SHIV 89.6P mucosal challenge. J. Viral 77(21), 11563–11577 (2003).
   Google Scholar
• Amara RR, Villinger F, Altman JD et al Control of a mucosal challenge and prevention of AIDS by a multi-protein DNA/MVA vaccine. Science 292(5514), 69–74 (2001).
   PubMed Web of Science ®Google Scholar
• Amara RR, Villinger F, Staprans SI et al Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J. Vim!. 76(15), 7625–7631 (2002).
   Google Scholar
• Barouch DH, Santra S, Kuroda MJ et al Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. I Vim!. 75(11), 5151–5158 (2001).
   Google Scholar
• Earl PL, Wyatt LS, Montefiori DC et al Comparison of vaccine strategies using recombinant env—gag—pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. Virology 294(2), 270–281 (2002).
   PubMed Web of Science ®Google Scholar
• Robinson HL, Montefiori D, Johnson RP et al Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nature Merl 5 (5), 526–534 (1999).
   PubMed Web of Science ®Google Scholar
• Hel Z, Venzon D, Poudyal M et al Viremia control following antiretroviral treatment and therapeutic immunization during primary 5IV251 infection of macaques. Natury Merl 6(10), 1140–1146 (2000).
   Google Scholar
• •Reviews the impact of therapeutic immunization in a macaque SW model.
   Google Scholar
• Hel Z, Nacsa J, Tsai WP et al Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques. Virology 304 (1), 125–134 (2002).
   Google Scholar
• Radaelli A, Nacsa J, Tsai WP et al Prior DNA immunization enhances immune response to dominant and subdominant viral epitopes induced by a fowlpox-based SIVmac vaccine in long-term slow-progressor macaques infected with SIVmac251. Vimlogy312(1), 181–195 (2003).
   Google Scholar
• Edghill-Smith Y, Venzon D, Karpova T et al Modeling a safer smallpox vaccination regimen, for human immunodeficiency virus type 1*-infected patients, in immunocompromised macaques. J. Infect. Dis. 188(8), 1181–1191 (2003).
   Google Scholar
• Kent SJ, Zhao A, Dale CJ et al A recombinant avipoxvirus HIV-1 vaccine expressing interferon-y is safe and immunogenic in macaques. Vaccine18(21), 2250–2256 (2000).
   Google Scholar
• Osterhaus AD, van Baalen CA, Gruters RA et al Vaccination with Rev and Tat against AIDS. Vaccine 17(20-21), 2713–2714 (1999).
   Google Scholar
• Cooney EL, Collier AC, Greenberg PD et al. Safety and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet (337), 567–572, (1991).
   PubMed Web of Science ®Google Scholar
• Cooney EL, McElrath MJ, Corey L et al Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Nat! Acad. Sci. 90,1882-1886 (1993).
   Google Scholar
• Graham BS, Belshe RB, Clements ML et al Vaccination of vaccinia-naive adults with HIV-1 gp160 recombinant vaccinia (HIVAC- le) in a blinded, controlled, randomized clinical trial. j Infect. Dis. (166), 244–252 (1992).
   Google Scholar
• El-Daher N, Keefer MC, Reichman RC, Dolin R, Roberts NJ Jr. Persisting human immunodeficiency virus-1 gp160-specific human T-lymphocyte responses including CD8+ cytotoxic activity after receipt of enveloped vaccines. J Infect. Dis. (168), 306–313 (1993).
   Google Scholar
• Graham BS, Matthews TJ, Belshe RB et al. Augmentation of HIV-1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160.1 Infect. Dis. (167), 533–537 (1993).
   Google Scholar
• Frey SE, Newman FK, Yan L, Belshe RB. Response to smallpox vaccine in persons immunized in the distant past. JAMA (289), 3295–3299 (2003).
   PubMed Web of Science ®Google Scholar
• de Bruyn G, Rossini AJ, Chiu Y, Holman D, Elizga ML, Frey SE, Burke D, Evans TG, Corey L Keefer MC. Safety profile of recombinant canarypox HIV vaccines. Vaccine (22), 704–713 (2004).
   PubMed Web of Science ®Google Scholar
• ••Comprehensive review of the safety profile of ALVAC in human studies.
   Google Scholar
• Goepfert P, Horton H, McElrath J et al Safety, tolerability and CD8+ T-cell immunogenicity of high dose live recombinant canarypox ALVAC-HIV vaccine (vCP1452) in healthy, HIV-1 uninfected adults. 10h Conference of Retroviruses and Opportunistic Infections, MA, USA (2003).
   Google Scholar
• Jin X, Ramanathan M Jr, Barsoum S et al Safety and Immunogenicity of ALVAC vCP1452 and Recombinant gp160 in newly human immunodeficiency virus type-1 infected patients treated with prolonged highly active retroviral therapy. J. Viral (76), 2206–2216 (2002).
   Google Scholar
• Levy Y, Gahery-Segard H, Durier C et al Immunological and virological efficacy of ALVAC-HIV 1433 and HIV lipopeptides (Lipo-6T) combined with SC IL-2 in chronically HIV-infected patients. Abstract, 10h Conference on Retm viruses and Opportunistic Infections, MA, USA (2003).
   Google Scholar
• LeGarff M, Gourlain K, Tubiana R et& Cross recognition of HIV specific CD8 responses in chronically HIV-1 infected patients immunized by an HIV-1-LAI recombinant canarypox vector (vCP1433). Abstract, 10h Conference on Retroviruses and Opportunistic Infections, MA, USA (2003).
   Google Scholar
• Tubiana R, Carcelin G, Vray M et al Therapeutic vaccination with ALVAC-HIV vCP1433: A recombinant canarypox vaccine in chronically HIV-1 infected patients treated with HAART: Vacciter (ANRS094). Abstract: 10h Conference on Retroviruses and Opportunistic Infections. MA, USA (2003).
   Google Scholar
• Kinloch-deLoes S, Perrin L, Hoen B et al Evaluation of two therapeutic HIV vaccination regimens in HAART-treated primary HIV infection subjects following analytical treatment interruption: a randomized, placebo-controlled study. Abstract. 11th Conference on Retroviruses and Opportunistic Infections, CA, USA (2004).
   Google Scholar
• Cosma A, Nagaraj R, Buhler S et al Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine (22), 21–29 (2003).
   PubMed Web of Science ®Google Scholar
• Cooper DA, Workman C, Puls R et al. Randomized, placebo-controlled, Phase Ulla evaluation of the safety, immunogenicity and antiretrovirological properties of an avipox virus vaccine expressing HIV gag-pol and interferon-yin HIV-1 infected subjects. Abstract. 1 1 th Conference on Retroviruses and Opportunistic Infections, CA, USA (2004).
   Google Scholar
• Radaelli A. et al Humoral and cell-mediated immunity in rabbits immunized with live non-replicating avipox recombinants expressing the HIV-15F2 env gene. Vaccine (12), 1110–1117 (1994).
   PubMed Web of Science ®Google Scholar
• Graham BS, Matthews TJ, Belshe RB et al. Augmentation of human immunodeficiency virus type 1* neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgpl 60 in vaccinia-naive adults. J Infect. Dis. (167), 533–537 (1993).
   Google Scholar
• Pialoux G, Excler JL, Riviere Y etal. A prime-boost approach to HIV preventive vaccine using a recombinant canarypoxvirus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res. Hum. Retrovir. 11,373-381 (1995).
   Google Scholar
• Clements-Mann ML. Weinhold K, Matthews TJ, Graham BS, Gorse GJ et al Immune responses to human immunodeficiency virus (HIV) type 1* induced by canarypox expressing HIV-1M gp120, HIV-15F2 recombinant gp120, or both vaccines in seronegative adults. J Infect. Dis. 177, 1230–1246 (1998).
   Google Scholar
• Excler JL and Plotkin S. The prime—boost concept applied to HIV preventive vaccines. AIDS'll(Suppl. A), S127—S137 (1997).
   Google Scholar
• Slobod KS, Lackey TD, Howlett N et al. Clinical evaluation of the first multi-envelope HIV-1 vaccine: a 23 envelope recombinant vaccinia virus cocktail. Abstract, AIDS Vaccine 2003, NY, USA (2003).
   Google Scholar
• Ackers ML, Parekh B, Evans TG et al Human immunodeficiency virus (HIV) seropositivity among uninfected HIV vaccine recipients. J. Infect. Dis. (187), 879–886 (2003).
   PubMed Web of Science ®Google Scholar
• Sullivan P, Rossini T, deBruyn G et al Vaccine-induced positive HIV serology among participants in 10 clinical trials of canarypox-vectored HIV vaccine trials in the US. 10' Conference on Retroviruses and Opportunistic Infections, MA, USA Abstract (2003).
   Google Scholar
• Ockenhouse CF, Sun p, Lanar DE et al Phase Vila safety, immunogenicity and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect. Dir. 177,1664-1673 (1998).
   Google Scholar
• The AIDS Vaccine Evaluation Group 022 Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1* Env, Gag and Pro in combination with rgp120. J Infect. Dis. (183), 563–570 (2001).
   Google Scholar
• Gupta K, Hudgens M, Corey L et al AIDS vaccine evaluation group. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in as diverse population of HIV-1 uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic. Synth: 29,254-261 (2002).
   Google Scholar
• Belshe RB, Gorse GJ, Mulligan MJ et al Induction of immune responses to HIV-1 by canarypoxvirus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AID512, 2407–2415 (1998).
   Google Scholar
• Evans TG, Keefer MC, Weinhold KJ et al A canarypox vaccine expressing multiple human immunodeficiency virus type 1* genes given alone or with Rgp120 elicits broad and durable CD8+ cytotoxic T-lymphocyte responses in seronegative volunteers. J Infect. Dis. 180,290-298 (1999).
   Google Scholar
• Ferrari G, Humphrey W, McElrath J et al Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T-lymphocyte reactivities in uninfected volunteers. Proc. Natl Acaci Sc]. (94), 1396–1401 (1997).
   Google Scholar
• Cao H, Kaleebu P, Horn D et al. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV network for prevention trials 007 vaccine study. I Infect. Dis. (187), 887–895 (2003).
   Google Scholar
• Musey L, Ding Y, Elizaga M et al. HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T-cell immunity in HIV-1 uninfected individuals. Immund 1710,1094–1101 (2003).
   Google Scholar
• •Documents mucosal T-cell immunity following systemic administration of ALVAC-based vaccine candidate.
   Google Scholar
• Kaslow RA, Rivers C, Tang J et al. Polymorphisms in HLA class I genes associated with both favourable prognosis of human immunodeficiency virus (HIV) type 1* infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. j Viral 75,8681–8689 (2001).
   PubMed Web of Science ®Google Scholar
• Ahmed R, Butler LD, Bhatti L. T4+ T-helper cell function in vivo: differential requirement for induction of antiviral cytotoxic t-cell and antibody responses. Viral. 62,2102-2106 (1988).
   Google Scholar
• Rahemtulla A, Fung-Leung WP, Schilham MW et al Normal development and function of CD8+ cells but markedly decreased helper cell activity in mice lacking CD4. Nature 353,180–184 (1991).
   PubMed Web of Science ®Google Scholar
• Matloubian M, Concepcion RJ, Ahmed R. CD4+ T-cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. I Viral. 68,8056-8063 (1994).
   Google Scholar
• Goorse GJ, Patel GB, Mandava MD et al. Cytokine responses to human immunodeficiency virus type 1* (HIV-1) induced by immunization with live recombinant canarypoxvirus vaccine expressing HIV-1 genes boosted by HIV-1SF2 recombinant gp120. Vaccine 19, 1806–1819 (2001).
   Google Scholar
• Sabbaj S, Mulligan MJ, Hsieh RII et al. Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime—boost HIV-1 vaccine. 41D5 (14) 1365–1374, (2000).
   Google Scholar
• Goujard C, Marcellin F, Chavez H et al HIV immune and virological responses following the administration of IL-2 either alone or combined to ALVAC-HIV 1433 and HIV lipopeptides (LIPO6T) in patients treated early with HAART during primary infection: the ANRS 095 randomized trial. 11th Conference on Retro viruses and Opportunistic Infections, CA, USA, Abstract (2004).
   Google Scholar
• Letvin NL. Strategies for an HIV vaccine. J. Clin. Invest. 110,15–20 (2002).
   PubMed Web of Science ®Google Scholar
• Levy J. What can be achieved with an HIV vaccine? Lancet 357,223–224 (2001).
   PubMed Web of Science ®Google Scholar
• Desrosiers RC. Prospects for and AIDS vaccine. Nature Med. 10,221–223 (2004).
   PubMed Web of Science ®Google Scholar